局部晚期前列腺癌手术治疗策略及疗效

doi:10.6040/j.issn.1671-7554.0.2018.1226

摘要/Abstract

摘要： 前列腺癌是全球男性最常见的恶性肿瘤之一。局部晚期前列腺癌是指肿瘤突破了前列腺包膜,侵犯精囊或邻近组织(T_3a-T₄),和/或合并有区域淋巴结转移,没有远处转移的前列腺癌(cT_3a-4N_0-1M₀)。局部晚期前列腺癌恶性程度高,复发转移率高。过去由于较高的手术切缘阳性率和术后并发症发生率,局部晚期前列腺癌不推荐手术治疗。然而,手术技术的改进及综合内分泌治疗使得这些患者的预后优于局部放疗或放疗联合内分泌治疗。主要针对局部晚期前列腺癌外科治疗的合理性与优势、预后、扩大淋巴结清扫意义及并发症等进行述评。

关键词: 局部晚期前列腺癌, 手术治疗, 疗效

Abstract: Prostate cancer is the most common malignancy in men worldwide. Locally advanced prostate cancer is characterized by extracapsular extension(pT_3a), invasion of the seminal vesicles(pT_3b), invasion of adjacent organs 山东大学学报 (医学版)57卷1期 -姚旭东.局部晚期前列腺癌手术治疗策略及疗效 \=-(T₄), and/or positive regional lymph node but no distant metastasis. Locally advanced prostate cancer shows remarkably malignant behavior and a high rate of recurrence and metastasis. In the past, surgical treatment was considered unfavorable for locally advanced prostate cancer due to the high positive surgical margin rates and increased complication rates. However, improvements in surgical techniques and combined endocrine therapy have enabled the outcomes for these patients as compared to local radiotherapy or radiotherapy combined with endocrine therapy. This paper reviews the rationality and advantages, prognosis, extensive lymph node dissection, and complications of surgical treatment in patients with locally advanced prostate cancer.

Key words: Locally advanced prostate cancer, Surgical treatment, Efficacy

中图分类号:

R699

姚旭东. 局部晚期前列腺癌手术治疗策略及疗效[J]. 山东大学学报 (医学版), 2019, 57(1): 21-25.

YAO Xudong. Strategy and efficacy of surgical treatment in locally advanced prostate cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 21-25.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Chen R, Ren SC, Chinese Prostate Cancer Consortium, et al. Prostate cancer in Asia: a collaborative report[J]. Asian J Urol, 2014, 1(1): 15-29.
[4] DAmico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer[J]. JAMA, 2000, 284(10): 1280-1283.
[5] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2017, 71(4): 618-629.
[6] Veeratterapillay R, Goonewardene SS, Barclay J, et al. Radical prostatectomy for locally advanced and metastatic prostate cancer[J]. Ann R Coll Surg Engl, 2017, 99(4): 259-264.
[7] Suardi N, DellOglio P, Gallina A, et al. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups[J]. Urol Oncol, 2016, 34(2): 57.e1-57.e7. doi:10.1016/j.urolonc.2015.08.019.
[8] Hager B, Kraywinkel K, Keck B, et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study[J]. Prostate Cancer Prostatic Dis, 2017, 20(1): 61-66.
[9] Mitchell CR, Boorjian SA, Umbreit EC, et al. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer[J]. BJU Int, 2012, 110(11): 1709-1713.
[10] Srivatsa N, Nagaraja H, Shweta S, et al. Radical prostatectomy for locally advanced prostate cancers-review of literature[J]. Indian J Surg Oncol, 2017, 8(2): 175-180.
[11] Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy[J]. Eur Urol, 2009, 55(2): 261-270.
[12] Nickers P, Lartigau E. Re: Chao-Yu Hsu, Steven Joniau, Raymond Oyen et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007; 51: 121-9[J]. Eur Urol, 2007, 52(2): 612. doi:10.1016/j.eururo.2007.03.048.
[13] Freedland SJ, Partin AW, Humphreys EB, et al. Radical prostatectomy for clinical stage T3a disease[J]. Cancer, 2007, 109(7): 1273-1278.
[14] Joniau S, Hsu CY, Gontero P, et al. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors[J]. Scand J Urol Nephrol, 2012, 46(3): 164-171.
[15] Moltzahn F, Karnes J, Gontero P, et al. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients[J]. Prostate Cancer Prostatic Dis, 2015, 18(1): 31-37.
[16] Johnstone PA, Ward KC, Goodman M, et al. Radical prostatectomy for clinical T4 prostate cancer[J]. Cancer, 2006, 106(12): 2603-2609.
[17] Sussman R, Carvalho FLF, Harbin A, et al. Survival and secondary interventions following treatment for locally-advanced prostate cancer[J]. Can J Urol, 2018, 25(5): 9516-9524.
[18] Moschini M, Briganti A, Murphy CR, et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy[J]. Eur Urol, 2016, 69(2): 193-196.
[19] Gözen AS, Akin Y, Ates M, et al. Impact of laparoscopic radical prostatectomy on clinical T3 prostate cancer: experience of a single centre with long-term follow-up[J]. BJU Int, 2015, 116(1): 102-108.
[20] Mayor de Castro J, Caño Velasco J, Aragón Chamizo J, et al. Locally advanced prostate cancer. Definition, diagnosis and treatment[J]. Arch Esp Urol, 2018, 71(3): 231-238.
[21] Zhao F, Shen JY, Yuan ZG, et al. Trends in treatment for prostate cancer in China: preliminary patterns of care study in a single institution[J]. J Cancer, 2018, 9(10): 1797-1803.
[22] Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study[J]. Eur Urol, 2008, 53(1): 118-125.
[23] Kim KH, Rha KH. Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013; 63: 450-8[J]. Eur Urol, 2013, 64(3): e55-e56. doi:10.1016/j.eururo.2013.05.038.
[24] Moschini M, Fossati N, Abdollah F, et al. Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection[J]. Prostate Cancer Prostatic Dis, 2016, 19(1): 63-67.
[25] Pang C, Guan YY, Li HB, et al. Urologic cancer in China[J]. Jpn J Clin Oncol, 2016, 46(6): 497-501.
[26] Yao XD, Liu XJ, Zhang SL, et al. Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer[J]. Asian J Androl, 2013, 15(2): 241-245.
[27] Gandaglia G, De Lorenzis E, Novara G, et al. Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer[J]. Eur Urol, 2017, 71(2): 249-256.
[28] 潘家骅, 迟辰斐, 董柏君, 等. 多西他赛联合全雄阻断新辅助疗法治疗高危局部进展性前列腺癌的安全性[J]. 上海交通大学学报(医学版), 2017, 37(6): 797-802. PAN Jiahua, CHI Chenfei, DONG Baijun, et al. Safety of neoadjuvant chemo-hormonal therapy by the combination of docetaxel and maximal androgen blockage for locally advanced prostate cancer[J]. Journal of Shanghai Jiaotong University(Medical Science), 2017, 37(6): 797-802.

相关文章 15

[1]	孙继业,王紫欧,孙晓伟,李洪涛. 中药熏蒸联合体外冲击波对72例髋关节撞击综合征临床疗效、血清炎症因子水平的影响[J]. 山东大学学报 (医学版), 2022, 60(4): 76-81.
[2]	李青,林雪艳,刘天航,李晓文,范明喆,赵瑞瑞,田永杰. 经阴道网片盆底重建术的疗效中长期随访[J]. 山东大学学报 (医学版), 2022, 60(3): 71-75.
[3]	王沂峰,何丽清. 外阴癌腹股沟淋巴结手术的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 103-109,116.
[4]	王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118.
[5]	苗壮,刘培来,卢群山,姚天笑,李松林,罗德素. 双柱活动型单髁假体治疗膝关节内侧骨关节炎的早期疗效分析[J]. 山东大学学报 (医学版), 2021, 59(5): 90-95.
[6]	罗应舒,李宾,许昌芹,姜军梅,许洪伟. 240例上消化道黏膜下肿瘤内镜治疗的疗效及并发症评估[J]. 山东大学学报 (医学版), 2021, 59(3): 74-80.
[7]	霍素霞,刘薇,王鑫. 86例Ⅲ型瘢痕妊娠诊治体会[J]. 山东大学学报 (医学版), 2021, 59(1): 40-44.
[8]	褚勇,孙云. 后腹腔镜肾部分切除术治疗肾肿瘤的临床效果[J]. 山东大学学报 (医学版), 2018, 56(9): 83-86.
[9]	耿二冬,宁涓. 阿替洛尔对急性冠脉综合征合并心律失常患者的临床疗效及预后影响[J]. 山东大学学报 (医学版), 2018, 56(5): 70-73.
[10]	聂牧,倪晓菲,秦平,杨丹丹,李强,侯明,彭军,张晓琳,石艳. 单次利妥昔单抗治疗原发免疫性血小板减少症的疗效及安全性[J]. 山东大学学报 (医学版), 2018, 56(5): 81-84.
[11]	潘世扬. 肺癌疗效评价标志物的研究进展[J]. 山东大学学报 (医学版), 2018, 56(10): 31-39.
[12]	律慧敏,张梦玮,牛李敏,曾惠爱,闫敏. 国产多西他赛单药治疗晚期乳腺癌的疗效及安全性[J]. 山东大学学报 (医学版), 2018, 56(1): 45-49.
[13]	底学敏,牛书雷,赵静,杜随,于慧敏,张宏涛,王娟. CT引导下¹²⁵I粒子植入治疗晚期胃癌淋巴结转移[J]. 山东大学学报（医学版）, 2017, 55(9): 79-84.
[14]	赵文博,甄长青,袁代,单宁宁,王娜,封丽丽,李沛沛,丁梅,李英,张凌岩,王欣. 膦甲酸钠治疗血液病患者合并EB病毒感染的临床疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 96-99.
[15]	颜进项,孟雷,董亚南,张爱军,岳洪胜,李波,钟良君,白爱国. 优化救治流程与Solitaire FR支架在治疗急性脑动脉闭塞中的应用[J]. 山东大学学报（医学版）, 2017, 55(7): 49-54.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed